Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance

International Journal of Cancer

Volumn 135, Issue 10, 2014, Pages 2294-2304

  Queiroz, Karla C S ^a   Shi, Kun ^a   Duitman, JanWillem ^a   Aberson, Hella L ^a   Wilmink, Johanna W ^b   Van Noesel, Carel J M ^b   Richel, Dick J ^b   Spek, C Arnold ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chemoresistance; Macrophage; Microenvironment; Protease activated receptors

Indexed keywords

GEMCITABINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 1; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER MODEL; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; FIBROBLAST; HUMAN; HUMAN CELL; MACROPHAGE; METASTASIS; MONOCYTE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMORESISTANCE; DISEASE COURSE; DISEASE MODEL; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; KNOCKOUT MOUSE; LIVER TUMOR; METABOLISM; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTEASE ACTIVATED RECEPTORS; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

CHEMORESISTANCE; MACROPHAGE; MICROENVIRONMENT; PROTEASE ACTIVATED RECEPTORS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 84909950333     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28726     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Society AC. Cancer facts & figures. Atlanta: American Cancer Society, 2011.
3. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56:1134-52.
4. Burris HA3, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
5. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-18.
6. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53.
7. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
8. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008;153(Suppl 1):S263-S282.
9. Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-13.
10. Cisowski J, O'Callaghan K, Kuliopulos A, et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 2011;179:513-23.
11. Ghio P, Cappia S, Selvaggi G, et al. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. Clin Lung Cancer 2006;7:395-400.
12. Grisaru-Granovsky S, Salah Z, Maoz M, et al. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005;113:372-8.
13. Black PC, Mize GJ, Karlin P, et al. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007;67:743-56.
14. Eroglu A, Karabiyik A, Akar N. The association of protease activated receptor 1 gene -506 I/D polymorphism with disease-free survival in breast cancer patients. Ann Surg Oncol 2012;19:1365-9.
15. Du X, Wang S, Lu J, et al. Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. Jpn J Clin Oncol 2011;41:1086-93.
16. Massi D, Naldini A, Ardinghi C, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 2005;36:676-85.
17. Fujimoto D, Hirono Y, Goi T, et al. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res 2008;28:847-54.
18. Yang E, Boire A, Agarwal A, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009;69:6223-31.
19. Villares GJ, Zigler M, Wang H, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008;68:9078-86.
20. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
21. Mahadevan D, Hoff Von DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97.
22. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008;153(Suppl 1):S367-S378.
23. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005;166:1353-65.
24. Mercer PF, Johns RH, Scotton CJ, et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:414-25.
25. Snead AN, Insel PA. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J 2012;26:4540-7.
26. Rullier A, Gillibert-Duplantier J, Costet P, et al. Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008;294:G226-G235.
27. Fiorucci S, Antonelli E, Distrutti E, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004;39:365-75.
28. Trejo J, Connolly AJ, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996;271:21536-41.
29. Borensztajn K, Stiekema J, Nijmeijer S, et al. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 2008;172:309-20.
30. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997;272:31138-48.
31. Griffin CT, Srinivasan Y, Zheng YW, et al. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001;293:1666-70.
32. Yin YJ, Salah Z, Maoz M, et al. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J 2003;17:163-74.
33. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
34. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
35. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918-26.
36. Tang X, Mo C, Wang Y, et al. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2012; 138:93-104.
37. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-66.
38. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011;332:1284-8.
39. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870-5.
40. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res 2012;18:4266-76.
41. Olson P, Chu GC, Perry SR, et al. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA 2011;108:E1275-E1284.
42. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009;361:2094-6.
43. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012;2:260-9.
44. Queiroz KC, Spek CA, Peppelenbosch MP. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. Drug Resist Updat 2012;15:211-22.
45. D'Andrea MR, Derian CK, Santulli RJ, et al. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001;158:2031-41.
46. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012;33:119-26.
47. Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 2012;126:83-91.
48. Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16:3420-30.
49. Hanada T, Nakagawa M, Emoto A, et al. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000;7:263-9.
50. Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011;167:e211-e219.
51. Ikeda O, Egami H, Ishiko T, et al. Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. Int J Oncol 2003;22:295-300.
52. Shimamoto R, Sawada T. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 2004; 24:1401-6.
53. Darmoul D, Gratio V, Devaud H, et al. Protease-activated receptor 2 in colon cancer trypsin-induced mapk phosphorylation and cell proliferation are mediated by epidermal. J Biol Chem 2004;279:20927-34.
54. Shi K, Queiroz KCS, Stap J, Richel DJ, Spek CA. Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. J Thromb Haemost 2013;11:1892-902.